DNAGinkgo Bioworks Holdings Inc - Ordinary Shares - Class A
$9.17
$0.62
(7.25%)
Closed $9.17
$0.17
(1.85%)
After Hours
EarningsAug 6
Mkt Cap$599.03M
Vol1.55M
Fundamentals
About
Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
Sector:
Health Services
Industry:
Medical Or Nursing Services
Employees:
485
Frequently Asked Questions
What is Market Cap of Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A?
What is the 52-week high for Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A?
What is the 52-week low for Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A?
What is Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A stock price today?
What was Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A stock price yesterday?
What is the PE ratio of Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A?
What is the Price-to-Book ratio of Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A?
What is the 50-day moving average of Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A?
How many employees does Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A have?
Advertisement|Remove ads.
Latest DNA News
ViewGinkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
PR Newswire
The $59B Quiet Shift Reshaping How Patients Access Care
PR Newswire
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
PR Newswire
Advertisement|Remove ads.